Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

• Published in: Hepatology (Baltimore, Md.) Vol. 44; no. 6; pp. 1656 - 1665
• Main Authors: Colonno, Richard J., Rose, Ronald, Baldick, Carl J., Levine, Steven, Pokornowski, Kevin, Yu, Cheng F., Walsh, Ann, Fang, Jie, Hsu, Mayla, Mazzucco, Charles, Eggers, Betsy, Zhang, Sharon, Plym, Mary, Klesczewski, Kenneth, Tenney, Daniel J.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2006; Wiley
• Subjects: Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - therapeutic use; Biological and medical sciences; DNA, Viral - analysis; Drug Resistance, Viral; Guanine - analogs & derivatives; Guanine - therapeutic use; Hepatitis B e Antigens - immunology; Hepatitis B virus - drug effects; Hepatitis B, Chronic - drug therapy; Human viral diseases; Humans; Infectious diseases; Lamivudine - therapeutic use; Medical sciences; Nucleosides; Pharmacology. Drug treatments; Treatment Outcome; Viral diseases; Viral hepatitis; Infection; Human; Viral hepatitis B; Resistance; Viral disease; Entecavir; Nucleoside analog; Digestive diseases; Hepatic disease; Antiviral; Nucleoside
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.21422

Comprehensive monitoring of genotypic and phenotypic antiviral resistance was performed on 673 entecavir (ETV)‐treated nucleoside naïve hepatitis B virus (HBV) patients. ETV reduced HBV DNA levels to undetectable by PCR (<300 copies/mL, <57 IU/mL) in 91% of hepatitis B e antigen (HBeAg)‐positive and ‐negative patients by Week 96. Thirteen percent (n = 88) of the comparator lamivudine (LVD)‐treated patients experienced a virologic rebound (≥1 log increase from nadir by PCR) in the first year, with 74% of these having LVD resistance (LVDr) substitutions evident. In contrast, only 3% (n = 22) of ETV‐treated patients exhibited virologic rebound by Week 96. Three ETV rebounds were attributable to LVDr virus present at baseline, with one having a S202G ETV resistance (ETVr) substitution emerge at Week 48. None of the other rebounding patients had emerging genotypic resistance or loss of ETV susceptibility. Genotyping all additional ETV patients with PCR‐detectable HBV DNA at Weeks 48, 96, or end of dosing identified seven additional patients with LVDr substitutions, including one with simultaneous emergence of LVDr/ETVr. Generally, ETV patients with LVDr were detectable at baseline (8/10) and most subsequently achieved undetectable HBV DNA levels on ETV therapy (7/10). No other emerging substitutions identified decreased ETV susceptibility. In conclusion, ETVr emergence in ETV‐treated nucleoside naïve patients over a 2‐year period is rare, occurring in two patients with LVDr variants. These findings suggest that the rapid, sustained suppression of HBV replication, combined with a requirement for multiple substitutions, creates a high genetic barrier to ETVr in nucleoside naïve patients. (HEPATOLOGY 2006;44:1656–1665.)